Bolt Biotherapeutics (NASDAQ:BOLT) reported quarterly losses of $(4.46) per share which beat the analyst consensus estimate of $(6.27) by 28.83 percent. This is a 60.18 percent increase over losses of $(11.20) per share from the same period last year. The company reported quarterly sales of $1.80 million which beat the analyst consensus estimate of $819.75 thousand by 120.07 percent. This is a 41.49 percent increase over sales of $1.27 million the same period last year.